Browse the evidence

Use of GLP-1 receptor agonists (GLP-1 RAs) is associated with an increased risk of gallbladder or biliary diseases (RR, 1.37; 95% CI, 1.23-1.52).

Healthcare providers should be aware of the potential increased risk of gallbladder diseases when prescribing GLP-1 RAs.

GLP-1 RA use is associated with a higher risk of gallbladder or biliary diseases at higher doses (RR, 1.56; 95% CI, 1.36-1.78) compared to lower doses (RR, 0.99; 95% CI, 0.73-1.33).

Dosing strategies for GLP-1 RAs should consider the potential increased risk of gallbladder diseases.

GLP-1 RA use remained low overall for treatment of T2D, particularly among patients with ASCVD.

Clinicians should recognize the need for increased GLP-1 RA prescribing, especially for patients with ASCVD.

Obesity is a major contributor to primary hypertension through mechanisms such as neurohormonal activation, inflammation, and kidney dysfunction.

Addressing obesity is crucial for managing hypertension risk.

Lifestyle modifications have limited long-term success in reducing adiposity and blood pressure in patients with obesity.

Practitioners should consider alternative strategies beyond lifestyle modifications for effective obesity management.

Adding protein or additional carbohydrate to a feeding strategy providing 1.2 g CHO x kg(-1) x h(-1) did not enhance glycogen resynthesis during recovery.

Practitioners should note that simply adding protein or extra carbohydrates may not improve glycogen recovery beyond recommended carbohydrate intake.

One-year discontinuation was significantly higher for patients without type 2 diabetes (64.8%) compared with those with type 2 diabetes (46.5%).

Practitioners should be aware that patients without type 2 diabetes may struggle more with adherence to GLP-1 RA therapy.

The association between glycemic load and cardiovascular events was similar to that of glycemic index among participants with cardiovascular disease at baseline, but not significant among those without preexisting cardiovascular disease.

Glycemic load may be a relevant factor for cardiovascular risk in individuals with existing conditions, but less so for those without.

Satiation is associated with preferentially increased neuronal activity in the prefrontal cortex.

Recognizing the role of the prefrontal cortex in satiation can inform strategies for managing eating behaviors.

Brain responses to hunger and satiation may differ between obese and lean individuals.

Understanding these differences can aid in developing tailored approaches for obesity treatment.

Insulin regulates free fatty acid appearance into plasma (FFA R(a)) by inhibition of lipolysis while maintaining a constant rate of primary FFA reesterification.

Practitioners should consider insulin's role in regulating free fatty acid levels through lipolysis inhibition.

Lipolysis, free fatty acid appearance into plasma (FFA R(a)), and secondary free fatty acid reesterification are exquisitely insulin sensitive.

Understanding the insulin sensitivity of these processes can help in managing metabolic health and conditions like diabetes.

Intervals at 100% PP and 80% PP do not produce statistically significant enhancements in performance.

Avoid relying on 100% and 80% PP intervals for performance gains in cycling time-trials.

Satiation in lean individuals is associated with increased neuronal activity in the prefrontal cortex.

Recognizing the role of the prefrontal cortex in satiation can inform strategies for managing eating behaviors.

Brain responses to hunger and satiation may differ between obese and lean individuals.

Understanding these differences can aid in developing tailored interventions for obesity management.

Resistance training frequency does not significantly or meaningfully impact muscle hypertrophy when volume is equated.

Individuals can choose their training frequency based on personal preference as it does not affect hypertrophy when volume is matched.

Omega-3 PUFA-derived mediators play a role in controlling inflammation and tissue homeostasis.

These mediators could be targeted for therapeutic strategies in inflammatory conditions.

Individuals with high diastolic blood pressure benefited more from bariatric surgery than those with low diastolic blood pressure.

Bariatric surgery may be particularly beneficial for obese patients with high diastolic blood pressure.

There were no correlations between energy balance and either carbohydrate or protein balances.

Practitioners should note that energy balance does not correlate with carbohydrate or protein intake in this context.

Fat, rather than carbohydrate or protein, is almost exclusively used or stored in response to day-to-day fluctuations in energy balance.

Practitioners should focus on fat metabolism when addressing energy balance fluctuations.

Understanding the weight loss effect of SGLT2 inhibitors can aid clinicians in optimal treatment decision-making.

Clinicians should consider weight loss effects when prescribing SGLT2 inhibitors.

There is a need for more accurate measures of muscle mass and function for diagnosing sarcopenia.

Practitioners should seek to utilize more accurate measurement tools for assessing sarcopenia.

No significant differences were noted in muscle thickness of the biceps brachii between the two training groups.

Both training methods may lead to similar muscle thickness outcomes.

There is a significant and growing public interest in Ozempic and related GLP-1 agonists.

Healthcare providers should be prepared for increased inquiries about these medications.